[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:adenovirus":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":41,"states":42},"Adenovirus",5,[7,15,21,28,35],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT03266627","Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection",[11],"Phase 2","RECRUITING","2026-08-26T02:18:32.765187Z","2026-05-05T02:43:29.200923Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":19,"content_modified":20},"NCT05664126","Haplo-identical Viral-Specific T-cells for Treatment of Cytomegalovirus and Adenovirus Infections After Hematopoietic Cell Transplantation",[11],"2026-08-26T02:19:20.945539Z","2026-05-05T02:35:31.877826Z",{"nct_id":22,"title":23,"phases":24,"status":12,"updated_at":26,"content_modified":27},"NCT03665675","Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT",[25],"Early Phase 1","2026-08-26T02:18:51.009190Z","2026-05-05T02:43:26.962006Z",{"nct_id":29,"title":30,"phases":31,"status":12,"updated_at":33,"content_modified":34},"NCT02048332","Donor-Derived Viral Specific T-cells (VSTs)",[32],"Phase 1\u002FPhase 2","2026-08-26T02:17:22.949982Z","2026-05-05T02:35:31.777346Z",{"nct_id":36,"title":37,"phases":38,"status":12,"updated_at":39,"content_modified":40},"NCT01306084","Viral Infections in Healthy and Immunocompromised Hosts",[],"2026-08-26T02:18:51.833592Z","2026-05-13T02:55:06.074123Z",[],[43],{"state":44,"count":45,"slug":46},"Ohio",3,"ohio"]